Sanofi (SNY) Equity Income (2009 - 2026)
Sanofi (SNY) posted Equity Income of -$2.2 billion for Q2 2026, down 194.62% sequentially from $2.3 billion in Q1 2026, and down 17920.65% YoY from N/an in Q2 2025.
Sanofi (SNY) Equity Income (2009 - 2026) Analysis & Trends
Sanofi has reported Equity Income for 18 years, with the latest figure at -$2.2 billion in Q2 2026.
- Quarterly Equity Income fell 17920.65% year-over-year to -$2.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.6 billion (up 18.31% YoY) and the FY2025 annual result came in at -$180.4 million, down 381.41% from the prior year.
- Equity Income declined to -$2.2 billion in Q2 2026 per SNY's latest filing, from $2.3 billion in the prior quarter.
- Over five years, Equity Income peaked at $8.3 billion in Q3 2025 and troughed at -$2.7 billion in Q2 2023.
- A 5-year average of $2.7 billion and a median of $2.6 billion in 2022 frame the typical range for Equity Income.
- The sharpest annual moves came in 2025 and 2026: Equity Income soared 121.07% in 2025, then slumped 17920.65% in 2026.
- Over 5 years, Equity Income stood at $6.5 billion in 2022, then rose by 3.86% to $6.7 billion in 2023, then gained by 6.42% to $7.2 billion in 2024, then grew by 0.43% to $7.2 billion in 2025, then slumped by 130.87% to -$2.2 billion in 2026.
- According to Business Quant data, Equity Income over the past three periods registered -$2.2 billion, $2.3 billion, and $7.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.03 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.22 Bn |
| Mar 31, 2026 | 2.35 Bn |
| Dec 31, 2025 | 7.19 Bn |
| Sep 30, 2025 | 8.29 Bn |
| Jun 30, 2025 | 12.45 Mn |
| Mar 31, 2025 | 2.27 Bn |
| Dec 31, 2024 | 7.16 Bn |
| Sep 30, 2024 | 3.75 Bn |
| Jun 30, 2024 | -1.12 Bn |
| Mar 31, 2024 | 1.23 Bn |
| Dec 31, 2023 | 6.73 Bn |
| Sep 30, 2023 | 3.30 Bn |
| Jun 30, 2023 | -2.73 Bn |
| Mar 31, 2023 | 2.64 Bn |
| Dec 31, 2022 | 6.48 Bn |
| Sep 30, 2022 | 2.70 Bn |
| Jun 30, 2022 | -2.53 Bn |
| Mar 31, 2022 | 2.60 Bn |
| Dec 31, 2021 | 7.30 Bn |
| Sep 30, 2021 | 3.48 Bn |